PD-1 blockade in recurrent or metastatic cervical cancer: Data from cemiplimab phase I expansion cohorts and characterization of PD-L1 expression in cervical cancer-Reference-Cited by-同舟云学术

PD-1 blockade in recurrent or metastatic cervical cancer: Data from cemiplimab phase I expansion cohorts and characterization of PD-L1 expression in cervical cancer

Published:2020-11 Issue:2 Volume:159 Page:322-328
ISSN:0090-8258
Container-title:Gynecologic Oncology
language:en
Short-container-title:Gynecologic Oncology

Author:

Rischin Danny,Gil-Martin Marta,González-Martin Antonio,Braña Irene,Hou June Y.,Cho Daniel,Falchook Gerald S.,Formenti Silvia,Jabbour Salma,Moore Kathleen,Naing Aung,Papadopoulos Kyriakos P.,Baranda Joaquina,Fury Wen,Feng Minjie,Stankevich Elizabeth,Li Jingjin,Yama-Dang N. Alice,Yoo Suk-Young,Lowy Israel,Mathias Melissa,Fury Matthew G.

Funder

Sanofi

Regeneron Pharmaceuticals

Publisher

Elsevier BV

Subject

Obstetrics and Gynaecology,Oncology

Reference20 articles.

1. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries;Bray;CA Cancer J. Clin.,2018

2. Integrated genomic and molecular characterization of cervical cancer;Burk;Nature,2017

3. Cervical cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up;Marth;Ann. Oncol.,2017

4. Improved survival with bevacizumab in advanced cervical cancer;Tewari;N. Engl. J. Med.,2014

5. Evaluation of pemetrexed (Alimta, LY231514) as second-line chemotherapy in persistent or recurrent carcinoma of the cervix: the CERVIX 1 study of the MITO (multicentre Italian trials in ovarian cancer and gynecologic malignancies) group;Lorusso;Ann. Oncol.,2010

Cited by 59 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and Safety of Iparomlimab, an Anti-PD-1 Antibody, in Patients with Advanced Solid Tumors: A Phase 1c Study;Advances in Therapy;2024-09-14

2. CDYL loss promotes cervical cancer aggression by increasing PD-L1 expression via the suppression of IRF2BP2 transcription;Translational Oncology;2024-09

3. Efficacy of PD-1 or PD-L1 inhibitors for the therapy of cervical cancer with varying PD-L1 expression levels: a single-arm meta-analysis;Frontiers in Oncology;2024-08-20

4. Immunotherapy for Recurrent and Metastatic Cervical Cancer: A Review;Clinical and Experimental Obstetrics & Gynecology;2024-07-11

5. Folate Receptor Alpha Expression and the Tumor Immune Microenvironment in Patients with Cervical Cancer;International Journal of Gynecological Pathology;2024-06-12